UMSARS versus laryngoscopy-based assessment of dysphagia
Objective: To compare the Unified Multiple System Atrophy Rating Scale (UMSARS) part I-item 2 with an ear/nose/throat (ENT) expert physician assessment. Background: Early and severe…Identifying a path to improve diagnostic delay and access to care for PSP, CBS, and MSA
Objective: To understand diagnosis and care experiences of patients and care partners living with progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and multiple system atrophy…Analysis of the therapeutic potential of c-Abl inhibition in Multiple System Atrophy
Objective: IkT-148009 is a potent selective inhibitor of non-receptor Abelson Tyrosine Kinases (c-Abl kinases). Our recent analysis of post-mortem brain tissue from patients with Multiple…Baseline characteristics for patients with multiple system atrophy entering a randomized, controlled study of the anti-α-synuclein monoclonal antibody Lu AF82422
Objective: Report baseline characteristics for patients with multiple system atrophy (MSA) entering a study to assess the safety and efficacy of alpha-synuclein (α-syn) monoclonal antibody…A multiple-dose thorough QT study to evaluate the effect of ampreloxetine on cardiac repolarization in healthy subjects
Objective: To characterize the effect of therapeutic and supratherapeutic doses of ampreloxetine on cardiac repolarization in healthy subjects. Background: Ampreloxetine is a potent NE reuptake…Determinants of care partner burden in atypical parkinsonian syndromes
Objective: To understand the determinants of burden among people caring for individuals diagnosed with progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), or multiple system atrophy…Short-term effect of continuous positive airway pressure in MSA patients with sleep disordered breathing
Objective: SBD are frequent in MSA, mainly represented by inspiratory stridor, obstructive and central sleep apnea/hypopnea syndrome (SAS), or hypopneaimpacting the quality of sleep. A…An Analysis of Subgroups of Multiple System Atrophy Patients from Ampreloxetine Phase 3 Trials
Objective: To present results in the subset of patients with multiple system atrophy (MSA) and relevant MSA subgroups from two ampreloxetine phase 3 trials for…Therapy-associated risk decision making in individuals with multiple system atrophy and Parkinson’s disease, THE YAMSA TRIAL
Objective: This study aimed to quantify the risk willingness of patients suffering from the α-synucleinopathies multiple system atrophy (MSA) and Parkinson's Disease (PD) and identify…The shaky truth of a Movement Disorder Nurse pilot program in Rural Australia
Objective: The conception of the Movement Disorder Nurse program began when the Australian Government and Fight Parkinson’s conducted a scoping evaluation of people living with…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 10
- Next Page »